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A B S T R A C T
Purpose
To determine whether prolonged androgen suppression (AS) duration before radiotherapy
improves survival and disease control in prostate cancer.
Patients and Methods
One thousand five hundred seventy-nine men with intermediate-risk prostate cancer were
randomly assigned to 8 weeks of AS followed by radiotherapy with an additional 8 weeks of
concurrent AS (16 weeks total) or to 28 weeks of AS followed by radiotherapy with an additional
8 weeks of AS (36 weeks total). The trial sought primarily to detect a 33% reduction in the hazard
of prostate cancer death in the 28-week assignment. Time-to-event end points are reported for up
to 10 years of follow-up.
Results
There were no between-group differences in baseline characteristics of 1,489 eligible patients with
follow-up. For the 8- and 28-week assignments, 10-year disease-specific survival rates were 95% (95% CI,
93.3% to 97.0%) and 96% (95% CI, 94.6% to 98.0%; hazard ratio [HR], 0.81; P  .45), respectively, and
10-year overall survival rates were 66% (95% CI, 62.0% to 69.9%) and 67% (95% CI, 63.0% to 70.8%; HR,
0.95; P  .62), respectively. For the 8- and 28-week assignments, 10-year cumulative incidences of
locoregional progression were 6% (95% CI, 4.3% to 8.0%) and 4% (95% CI, 2.5% to 5.7%; HR, 0.65;
P  .07), respectively; 10-year distant metastasis cumulative incidences were 6% (95% CI, 4.0% to
7.7%) and 6% (95% CI, 4.0% to 7.6%; HR, 1.07; P  .80), respectively; and 10-year prostate-specific
antigen–based recurrence cumulative incidences were 27% (95% CI, 23.1% to 29.8%) and 27%
(95% CI, 23.4% to 30.3%; HR, 0.97; P  .77), respectively.
Conclusion
Extending AS duration from 8 weeks to 28 weeks before radiotherapy did not improve outcomes.
A lower than expected prostate cancer death rate reduced ability to detect a between-group
difference in disease-specific survival. The schedule of 8 weeks of AS before radiotherapy plus 8
weeks of AS during radiotherapy remains a standard of care in intermediate-risk prostate cancer.
J Clin Oncol 33:332-339. © 2014 by American Society of Clinical Oncology
INTRODUCTION
The Radiation Therapy Oncology Group (RTOG)
has a nearly four-decade history of prostate cancer
research, largely conducted through large-scale
randomized clinical trials. Investigation of various
androgen suppression (AS) regimens with radio-
therapy is a prominent endeavor of the RTOG,1-5
having established standards of care used world-
wide. Luteinizing hormone–releasing hormone an-
alog (LHRHa) agents are the principal means of
inducing the potentially reversible hypogonadal
state of AS. An antiandrogen is often added to block
the effects of residual androgens. Early studies dem-
onstrated the value of adding AS to radiotherapy in
locally advanced prostate cancer,1-3 and short-term
AS was found later to benefit some men with local-
ized disease as well.4
AS typically starts before radiotherapy,2-5 be-
cause exploratory analyses of its use in this way sug-
gested a promising line of research. Early studies
chose an 8-week duration of preradiotherapy AS,2-5
and AS was continued for an additional 8 weeks
during radiotherapy. Research in animal models
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showed subsequently that extending the duration of AS improved
cancer control when radiotherapy was then given.6 The RTOG sought
to translate this observation into a clinical trial testing the hypothesis
that prolonged-duration AS used before radiotherapy improves out-
comes in intermediate-risk prostate cancer.
PATIENTS AND METHODS
Trial Design and Participants
Men age  18 years with prostate adenocarcinoma were eligible if they
met one of the following criteria sets: clinical classification T1b-4 (according to
American Joint Committee on Cancer staging system, fifth edition),7 Gleason
score 2 to 6, and prostate-specific antigen (PSA) more than 10 but  100
ng/mL; T1b-4, Gleason score 7, and PSA less than 20 ng/mL; or T1b-1c,
Gleason score 8 to 10, and PSA less than 20 ng/mL. Additional criteria were no
nodal or distant metastatic disease, expected comorbidity survival duration of
 10 years, Zubrod performance status less than 2, serum ALT level  2
upper normal limit, and no prior bilateral orchiectomy, chemotherapy, radio-
therapy, cryosurgery, or definitive surgery for prostate cancer. Prior AS was not
allowed unless an LHRHa was started  30 days before random assignment
and bicalutamide or flutamide was started within 14 days of the LHRHa; any
finasteride was discontinued. Patients with another invasive cancer, other than
localized basal or squamous cell skin carcinoma, were not eligible unless
continually free of that cancer for  5 years. Before study entry, evaluation
required history and physical examination (including digital rectal examina-
tion), serum PSA (within 90 days before random assignment and before AS),
CBC, serum chemistry, bone scan, and assessment of Zubrod performance
status and regional lymph nodes with surgical sampling, computed tomogra-
phy, or magnetic resonance imaging.
After institutional review board approval at each center, participants
were recruited at 152 community-based and tertiary medical site members of
the RTOG. Membership was established and maintained through a quality-
control system compliant with National Cancer Institute (NCI) guidelines. All
participants provided written informed consent before registration and were
to receive protocol-specified care and follow-up at a member site. Participants
did not receive compensation for joining the study, and no commercial sup-
port was provided.
Random Assignment
This was a multicenter, stratified, open-label, parallel-group study with
1:1 random assignment approved and sponsored by the NCI. The RTOG was
responsible for design, administration, data collection, quality assurance, sta-
tistical analysis, interpretation of findings, and article preparation. Participants
were stratified according to PSA level ( 10 v  10 to 20 v  20 to  100
ng/mL), Gleason score (2 to 4 v 5 to 6 v 7 to 10), tumor stage (T1b-2 v T3-4),
and whether AS had been started (no v yes). Participants were then randomly
assigned using the permuted-block method8 either to AS for 8 weeks (short
duration) followed by radiotherapy with an additional 8 weeks of AS concur-
rently or to 28 weeks of AS (prolonged duration) followed by radiotherapy
with an additional 8 weeks of AS.
Treatment
Participants started AS within 6 weeks of random assignment. AS con-
sisted of a commercially available LHRHa (eg, goserelin, leuprolide) given by
intramuscular or subcutaneous injection according to formulary instructions.
Various dosing formulations were allowed to achieve the required total treat-
ment duration as assigned. Bicalutamide 50 mg once a day orally or flutamide
250 mg three times a day orally was started within 14 days of the first LHRHa
injection. Bicalutamide or flutamide was continued until the last day of
radiotherapy, which was for 16 weeks (maximum of 112 days) for the short-
duration group or 36 weeks (maximum of 252 days) for the prolonged-
duration group. These agents were discontinued if ALT increased to more than
twice the upper limit of normal.
Radiotherapy started 8 weeks after the first LHRHa injection in the
short-duration group and after 28 weeks in the prolonged-duration group.
Radiotherapy used two-dimensional or three-dimensional conformal external
technique (intensity modulation and brachytherapy were not allowed) with-
out requirement for image guidance. Computed tomography identified the
prostate, any extraprostatic tumor extensions, and pelvic anatomy. The radio-
therapy target was the prostate and any extraprostatic tumor extensions, with
a 1.0- to 1.5-cm margin. When lymph node assessment was based on imaging,
external and internal iliac lymph nodes and seminal vesicles were also targeted
if one of the following existed: T3-4, Gleason score 7, and PSA more than 4 but
 20 ng/mL; T3-4, Gleason score 6, and PSA more than 10 but  20 ng/mL;
T2a, Gleason score 7, and PSA more than 10 but  20 ng/mL; T1b-1c, Gleason
score 8 to 10, and PSA more than 10 but  20 ng/mL; or T2a-4, Gleason score
6, and PSA more than 20 ng/mL.
Registered and randomly assigned
(N = 1,579)
Assigned to 8-week AS  RT + AS
(n = 790)
Assigned to 28-week AS  RT and AS
(n = 789)
Eligible and available for evaluation
(n = 752)
Eligible and available for evaluation
(n = 737)
)032 = n( deiD
  Died as result of prostate cancer (n = 29)
  Died as result of treatment (n = 1)
    complications
)022 = n( deiD
  Died as result of prostate cancer (n = 23)
  Died as result of treatment (n = 1)
    complications
Excluded (n = 52)
  Did not meet (n = 46)
    inclusion criteria
  Withdrew consent (n = 5)
Excluded (n = 38)
  Did not meet (n = 35)
    inclusion criteria
  Non–study drug (n = 1)
    administered
  Withdrew consent (n = 1)
  No data (n = 1)
Fig 1. Enrollment, random assignment,
and follow-up of the study participants. AS,
androgen suppression; RT, radiotherapy.
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Radiotherapy doses were prescribed according to International Com-
mission on Radiation Units and Measurements reference points. The
prostate and any extraprostatic tumor extensions were to receive 70.2 Gy in
39 daily fractions. The iliac lymph nodes were to receive 46.8 Gy in 26
fractions, when included.
Patient Assessment and End Points
After starting AS, patients were evaluated every 2 months before radio-
therapy with history and examination, assessment of adverse events, and
serum PSA. Serum ALT and bilirubin were monitored monthly until AS was
completed. Adverse event monitoring occurred weekly during radiotherapy.
History and examination, assessment of adverse events, and PSA level mea-
surement were performed at the end of radiotherapy, every 3 months for the
first year, every 6 months the next 4 years, and then annually thereafter. Any
findings noted between scheduled evaluations were also recorded. Prostate
biopsy, radionuclide bone scan, computed tomography, or magnetic reso-
nance imaging was used to investigate clinical findings or serum PSA elevation.
These same tests with history, examination, and serum PSA were to be done if
there was disease progression.
The study was designed primarily to compare disease-specific survival
rate between assignments. Death was attributed to prostate cancer if certified
primarily as such, disease progressed on secondary AS, or death resulted from
an adverse effect of therapy. The cause of all deaths was reviewed by the study
chair, who was blinded to assignment.
Overall and disease-free survival, time to locoregional progression or
distant metastatic progression, time to biochemical failure and to biochemical
failure on secondary AS, and adverse treatment events were additional
between-group planned comparisons. Disease-free survival required the pa-
tient to be alive and without locoregional or metastatic disease or biochemical
failure. Biochemical failure was defined initially as serum PSA increasing on
three consecutive occasions from the nadir value.9 The study allowed analysis
with another definition if adopted through consensus subsequently, so the
criterion of PSA increasing  2 ng/mL above the nadir was also used.10
Biochemical failure on secondary AS was defined as a PSA increase of more
than 1 ng/mL on two or more consecutive measurements. Early adverse events
were defined by NCI Common Toxicity Criteria (version 2), and late events
were scored using the RTOG/European Organisation for Research and Treat-
ment of Cancer Late Radiation Morbidity Scoring schema.11
Statistical Methods
Sample size determination was based on disease-specific mortality, as-
suming 40% of deaths in the 8-week assignment would be from prostate
cancer and that 8-year disease-specific survival would be 79%.2 Two-hundred
seventy prostate cancer deaths were required to detect a 33% hazard reduction
in the 28-week assignment with 90% power using the log-rank test12 with a
two-sided significance level of P  .05. Under assumed failure rates, 1,540
patients accrued over 4 years and observed for an additional 6 years were
expected to provide the requisite events. This sample accounted for a 10%
ineligible or lack-of-data rate and three interim analyses. Interim reports were
provided to the Data Monitoring Committee every 6 months, with interim
efficacy and futility analyses performed at specific event number landmarks,
the first specified at 50 prostate cancer deaths. The boundary for early stopping
for efficacy was based on the O’Brien-Fleming  spending function ap-
proach,13 with low conditional power providing a basis for early stopping for
lack of efficacy.14
All eligible patients with follow-up were included and analyzed accord-
ing to assignment in this modified intent-to-treat analysis,15 with time-to-
event duration originating at random assignment and ending with data
received through December 2012. Overall and disease-free survival distribu-
tions were calculated using the Kaplan-Meier method.16 The cumulative inci-
dence estimator17 was used for all other end points to account for competing
risks. Treatment efficacy for disease-specific mortality was tested by compar-
ing cause-specific hazards with the log-rank statistic.12 Hazard ratios with 95%
CIs were computed using Cox proportional hazards18 or Fine-Gray compet-
ing risks hazards regression19 as appropriate.
RESULTS
Demographic Characteristics
Between February 2000 and May 2004, 1,579 patients were en-
rolled (Fig 1). Exclusions were mainly for the following reasons: AS
started early (47%), entry characteristics not met (24%), or testing
performed outside specified time frame (18%). Baseline characteris-
tics of 1,489 eligible participants with follow-up are listed in Table 1.
Ninety percent of patients had no physical limitation (Zubrod perfor-
mance score, 0), and 10% were limited in strenuous activity only
(Zubrod performance score, 1). Baseline characteristics were balanced
well, with no significant between-group differences.
Adherence to Assignment
Criteria for adherence to assigned therapy were established a
priori. AS was compliant if LHRHa total dosage was 80% to 120% of















Race or ethnic group
African American 129 17 117 16
Hispanic 14 2 15 2
White 595 79 594 81
Other or unknown 14 2 11 1
Tumor stage
T1b-c 387 52 370 50
T2 319 42 324 44
T3-4 46 6 43 6
Gleason score
2-6 202 27 201 27
7 466 62 463 63
8-10 84 11 73 10
Serum PSA, ng/mL
 10 352 47 343 47
10-20 333 44 324 44
 20 67 9 70 10
NCCN risk group
Intermediate 634 84 620 84
Single factor 344 54 337 46
Multiple factors 290 38 283 38
High 110 15 112 15
Very high 1 0·1 1 0·1
Prior AS
No 559 74 567 77
Yes 193 26 170 23
Nodal radiotherapy
No 640 85 611 83
Yes 112 15 126 17
Abbreviations: AS, androgen suppression; NCCN, National Comprehensive
Cancer Network; PSA, prostate-specific antigen.
Intermediate risk: T2b-2c, Gleason score 7, or PSA 10-20 ng/mL; high risk:
T3a, Gleason score 8 to 10, or PSA  20 ng/mL; very high risk: T3b-4.
Pisansky et al
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protocol specification. Six hundred forty-four participants (86%) in
the8-weekassignmentand647participants (88%)inthe28-weekassign-
ment were adherent; 56 participants (7%) in the 8-week assignment re-
ceived more than 120% of dosage, and 70 participants (10%) in the
28-week assignment received less than 80% of dosage. Median
radiotherapy dose to the prostate was 70.2 Gy (interquartile range,
70.2 to 70.2 Gy) in each group. Radiotherapy quality assurance was
performed in 29% of randomly selected patients from each group,
Table 2. Patient Outcomes by 10 Years According to Protocol-Assigned Therapy
End Point
8-Week AS ¡ Radiotherapy 
AS (n  752)
28-Week AS ¡ Radiotherapy 
AS (n  737)
Hazard Ratio 95% CI PNo. of Events 10-Year Rate (%) No. of Events 10-Year Rate (%)
Overall survival 230 66 220 67 0.95 0.79 to 1.15 .62
Intermediate risk 188 68 182 68 0.97 0.79 to 1.19 .75
Single factor 84 73 96 68 1.18 0.88 to 1.59 .26
Multiple factors 104 62 86 67 0.79 0.60 to 1.19 .11
High risk 39 58 38 61 0.97 0.62 to 1.51 .88
Disease-specific survival 30 95 24 96 0.81 0.48 to 1.39 .45
Intermediate risk 28 95 21 96 0.76 0.43 to 1.33 .33
Single factor 11 96 9 97 0.81 0.34 to 1.95 .64
Multiple factors 17 94 12 95 0.72 0.34 to 1.50 .38
High risk 2 97 3 97 1.61 0.28 to 9.29 .59
Disease-free survival
ASTRO (3 increases) 552 24 546 23 0.96 0.85 to 1.08 .47
ASTRO-RTOG 389 45 370 45 0.94 0.81 to 1.08 .37
Distant metastasis 38 6 40 6 1.07 0.68 to 1.66 .80
Intermediate risk 35 6 33 6 0.95 0.59 to 2.36 .84
Single factor 12 4 13 4 1.08 0.50 to 1.53 .84
Multiple factors 23 8 20 8 0.88 0.48 to 1.60 .67
High risk 3 4 7 7 2.44 0.63 to 9.52 .20
Locoregional progression 42 6 27 4 0.65 0.40 to 1.05 .07
Biochemical failure
ASTRO (3 increases) 409 56 428 59 1.02 0.89 to 1.17 .74
ASTRO-RTOG 192 27 185 27 0.97 0.79 to 1.19 .77
Intermediate risk 166 27 151 26 0.90 0.72 to 1.12 .35
Single factor 74 23 73 23 1.00 0.72 to 1.38 .99
Multiple factors 92 32 78 29 0.82 0.60 to 1.11 .20
High risk 24 23 32 31 1.45 0.86 to 2.46 .16
Second biochemical failure† 65 10 59 9 0.91 0.64 to 1.30 .62
Salvage therapy 161 22 151 22 0.94 0.76 to 1.18 .62
Abbreviations: AS, androgen suppression; ASTRO, American Society for Radiation Oncology; RTOG, Radiation Therapy Oncology Group.
Hazard ratios for disease-free and overall survival were determined using Cox proportional hazards regression; all others were determined using Fine-Gray
competing risks hazards regression.

















Time Since Random Assignment (years)
No. at risk
8-week AS 752 725 690 677 639 609 569 531 474 350 197
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Time Since Random Assignment (years)
No. at risk
8-week AS 752 729 703 689 652 621 579 538 477 351 198
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Fig 2. Estimates of (A) disease-specific survival and (B) overall survival. AS, androgen suppression; HR, hazard ratio.
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with no between-group difference in the 3% overall unacceptable
deviation rate.
Outcomes
Study end points and between-group comparisons are listed in
Table 2. Median follow-up duration was 9.4 years. Four hundred fifty
participants died, with prostate cancer accounting for 54 deaths
(12%), with 30 deaths (13%) in the 8-week group and 24 deaths (11%)
in the 28-week group. Disease-specific and overall survival differences
(log-rank P  .42 for disease-specific survival) between assignments
were not observed (Fig 2). The cumulative incidence of disease-
specific mortality within 10 years was 5% (95% CI, 3.0% to 6.7%) in
the 8-week group and 4% (95% CI, 2.0% to 5.4%) in the 28-week
group (hazard ratio, 0.81; 95% CI, 0.48 to 1.39; P  .45). The most
frequent causes of death were cardiovascular (23%), other cancerous
(21%), and pulmonary (9%) diseases; cause was entirely unknown in
two patients (0.4%). A difference in cause of death was not apparent
between groups. Extending AS to 28 weeks did not affect disease-free
survival, locoregional or distant metastatic disease progression, or the
incidence of biochemical failure (Fig 3).
Secondary Analyses
Post hoc subgroup analysis according to whether patients had
intermediate-risk (tumor stage T2b-2c, Gleason score 7, or PSA 10 to
20 ng/mL) or high-risk (clinical stage T3a, Gleason score 8 to 10, or
PSA  20 ng/mL) disease20 is shown in Table 2. The intermediate-risk
subgroup was stratified further into single intermediate-risk factor or
multiple-factor groupings, with outcomes provided similarly.20 There
were no differences in treatment effect (8 weeks v 28 weeks) for disease-
specific survival, cumulative incidence of distant metastasis, or biochem-
ical failure according to risk group, and no difference between risk groups
(intermediate v high risk) was evident within assignment.
Adverse Effects
The greatest severity of an adverse event at any time was reported
irrespective of its persistence or resolution subsequently. Early events
occurred from the start of AS through 90 days after radiotherapy, and
late events occurred thereafter. The higher incidence of early grade  2
adverseevents inthe28-weekassignment(P .001)wasattributedtoAS,
















Time Since Random Assignment (years)
No. at risk
8-week AS 752 706 644 593 540 491 448 402 347 250 146
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Time Since Random Assignment (years)
No. at risk
8-week AS 752 728 698 676 636 599 556 512 452 334 189
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Time Since Random Assignment (years)
No. at risk
8-week AS 752 729 698 679 640 608 566 522 464 343 194
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Time Since Random Assignment (years)
No. at risk
8-week AS 752 706 644 593 540 491 448 402 347 250 146
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Fig 3. Estimates of (A) disease-free survival and cumulative incidences of (B) locoregional progression, (C) distant metastasis, and (D) biochemical failure (nadir 
2 ng/mL). AS, androgen suppression; HR, hazard ratio.
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DISCUSSION
Men with intermediate- or high-risk prostate cancer are not typi-
cally candidates for active surveillance.21 Prior studies in these men
showed that radiotherapy with AS reduced the risk of death from
prostate cancer compared with radiotherapy alone,2,4,22,23 establishing
evidence-based guidelines for best medical practice. This study is part
of a long-range plan to build on prior research efforts, to confirm and
refine the findings of prior studies,4 and to improve outcomes with
new treatments, if possible. The RTOG noted previously that 8 weeks
of AS given before and also during radiotherapy reduced disease-
specific mortality.4 A post hoc exploratory analysis in that study sug-
gested that a subgroup of men with intermediate-risk disease derived
the greatest benefit from AS and that the 10-year disease-specific
survival was 97% compared with 90% with radiotherapy alone. Sim-
ilar 10-year disease-specific survival (95%) was observed in this study,
with a nearly identical incidence of biochemical failure (27% in this
study v 28% in previous RTOG study) noted between studies. Thus,
this study provides confirmatory testing and affirmation of the
exploratory analysis reported by Jones et al4 and also provides
reproducibility to enhance confidence in the outcomes achieved
with this treatment approach.
Basic research suggested that locoregional control of prostate
cancer is improved when prolonged-duration AS is given before ra-
diotherapy.6 This generated a hypothesis tested in this large-scale
parallel-group clinical study, in which a 28-week duration of preradio-
therapy AS was tested against the 8-week standard established previ-
ously.2,4 Prolongation of AS from 8 to 28 weeks before radiotherapy
and extending the total duration of AS from 16 to 36 weeks did not
further benefit patient outcomes across a broad measure of clinically
important end points. It may be reasoned that more treatment at
diagnosis may be warranted if cure is affected and secondary therapies
are used less frequently, but no evidence of such was apparent in this
study. The additional 20 weeks of AS led only to more medication use
(with the associated costs) and more endocrine (mainly hot flushing)
and sexual adverse effects.
This study has significant and broad implications for best medi-
cal practices. Healthcare providers may use this treatment approach
with confidence that its outcomes are accurate, reproducible, and
generalizable to their patients. Current guidelines recommend up to 6
months of AS with radiotherapy for intermediate-risk prostate cancer
based on evidence available before this report.22,23 A single meta-
analysis of 761 patients,24 which included some of these other tri-
als,22,23,25 concluded that 6 months of AS reduced prostate cancer
mortality compared with 3 or 4 months of AS. Other studies sought
also to determine the preferred duration of short-term AS,23,25,26 with
these investigations reaching different conclusions. However, the risk
profile of participants in these studies differed, as they did in our study
also, and this may account for varying observations and conflicting con-
clusions. This study provides the strongest evidence available to guide
short-term AS use with radiotherapy for intermediate-risk disease.
This study has several strengths. Patients were racially diverse,
varied in age, and recruited across a wide geographic distribution and
spectrum of medical practices, reflective of the population for whom
this intervention was eventually intended, providing generalizability
of study results. Patient accrual was robust and accomplished within
the predetermined time frame, with follow-up extended beyond that
originally required. The study also included several safeguards to as-
sure accuracy of the data and impartiality of its analysis, interpretation,
and reporting.
Nonetheless, some uncertainty in application of the findings
remains. The radiotherapy method prescribed more than a decade ago
Table 3. Adverse Events Associated With Treatment
Adverse
Event
8-Week AS ¡ Radiotherapy  AS
(early, n  747; late, n  742)
28-Week AS ¡ Radiotherapy  AS
(early, n  735; late, n  724)
P














Constitutional 139 19 31 4 1  1 179 24 54 7 1  1 .01
Endocrine 263 35 197 26 4  1 267 36 323 44 12 2  .001
GI 219 29 119 16 15 2 238 32 125 17 19 3 .43
Hepatic 92 12 32 4 16 2 122 17 24 3 6 1 .05
Sexual 12 2 12 2 60 8 21 3 38 5 122 17  .001
Urinary 269 36 168 22 33 4 270 37 190 26 37 5 .10
Any 230 31 311 42 120 16 143 20 366 50 189 26  .001
Late
Bladder 165 22 85 11 28 4 151 21 97 13 15 2 .89
GU, other 110 15 65 9 21 3 128 18 52 7 22 3 .45
Intestinal 151 20 40 5 7  1 155 21 37 5 7 1 1.00
GI, other 108 15 23 3 9 1 114 16 36 5 3  1 .40
Other 100 13 26 4 20 3 106 15 31 4 23 3 .54
Any 252 34 152 21 72 10 238 33 163 23 58 8 .82
NOTE. A patient may have more than one type of adverse event; five patients experienced a grade 4 (life-threatening) event. Grade 1 is mild; grade 2 is moderate;
and grade 3 is severe.
Abbreviations: AS, androgen suppression; GU, genitourinary.
Fisher’s exact test of between-group differences in grade  2 adverse events.
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is no longer recommended.20 It is likely that higher doses would
reduce biochemical failure and possibly salvage therapy,27 but studies
of higher doses have yet to demonstrate reduced prostate cancer–
specific mortality, which was the principal measure of efficacy in this
study. Advances in dose delivery have also occurred, allowing more
precise application of the prescribed dose to the intended target with
reduced exposure of adjacent normal organs. Thus, results of this
study may overestimate the incidence of biochemical failure, salvage
therapy, and adverse events expected today.
Consensus-based risk group definitions were largely introduced
(then changed) after our study was designed, so some study partici-
pants are now considered high risk.20 However, different outcomes
between the intermediate- and high-risk groups were not evident in
our study, irrespective of treatment assignment. Some investigators
recently proposed modifications to the intermediate-risk group
definition28-30 and postulated that certain patients may not benefit
from AS. Although our study cannot address this issue, the RTOG
is currently conducting a randomized clinical trial to formally test
this hypothesis.
This study provided the opportunity for incidental observations
important for interpreting the outcomes of radiotherapy with short-
term AS and for development and design of future studies. The method
used to define biochemical failure yielded substantial differences in esti-
mating some aspects of treatment outcome. The method of three consec-
utive serum PSA increases was the first consensus-based definition of
biochemical failure9 andtheonlyavailablemethodduringconductof this
study. It is now recognized that serum PSA often increases when short-
termASendsandtestosteronerecoveryensues.10Slightincreasesinserum
PSA have high sensitivity for biochemical failure, but specificity is lacking.
Although historically important, the successive consensus-based defini-
tion (nadir  2 ng/mL) should take its place.10
Disease-specific survival was favorable for both treatment groups
and much better than historical outcomes used in study design. Early
reporting of study results at the first planned interim analysis was
based on this, inspection of annualized cause-specific death rates, the
follow-up duration needed to reach this and subsequent planned
analyses, and greatly diminished prospects for observing the requisite
prostate cancer deaths for final analysis. This has significant implica-
tions for any future study that tests an alternative treatment strategy
using this outcome in intermediate-risk prostate cancer. These studies
must assume that the standard regimen of 8-week AS followed by
radiotherapy with 8 additional weeks of AS will yield a disease-specific
survival of 95% at 10 years. Reducing the hazard of death from pros-
tate cancer by 33%, as sought in this study, will require large study
cohorts (approximately 7,000 participants) with prolonged follow-up
requirements to a level that has yet to be even closely approximated.
Feasibility may demand a change in focus to research outcomes that
are less dependent on survival end points, a transition that has oc-
curred already in other cancer types.
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GLOSSARY TERMS
locoregional failure: failure at the primary site or the re-
gional lymphatics.
prostate-specific antigen (PSA): a protein produced by
cells of the prostate gland. The blood level of prostate-specific
antigen (PSA) is used as a tumor marker for men who may be suspected
of having prostate cancer. Most physicians consider 0 to 4.0 ng/mL to be
the normal range. Levels of 4 to 10 and 10 to 20 ng/mL are considered
slightly and moderately elevated, respectively. PSA levels have to be
complemented with other tests to make a firm diagnosis of prostate
cancer.
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